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22* Retrospective analysis of stored dried blood spots (Guthrie cards)
using IRT measurements to detect clinically diagnosed children
with cystic ﬁbrosis in Switzerland
J. Barben1, R. Fingerhut2, M.H. Schoeni3, T. Torresani2, Swiss CF Screening
Group. 1Children’s Hospital, Pulmonology, St. Gallen, Switzerland; 2University
Children’s Hospital, Swiss Newborn Screening, Zu¨rich, Switzerland; 3University
Hospital, Department of Pediatrics, Berne, Switzerland
Aims: To evaluate whether the planned two step newborn screening for cystic
ﬁbrosis (IRT − 7 most common DNA mutations) would have retrospectively
detected all clinically diagnosed children with CF in Switzerland in the last 3 years.
Methods: A questionnaire was mailed to all CF centres to collect all names of
children who were diagnosed with CF based on clinical symptoms and two positive
sweat tests (or 2 gene mutations) since 1st January 2006, when general newborn
screening was centralised in Switzerland. Afterwards, IRT was measured in stored
dried blood spots from the 4th day of life (Guthrie cards) of these children using
AutoDELFIA Neonatal IRT-Kit (PerkinElmer, Finnland).
Results: 57 children with clinically diagnosed CF were reported from the CF
centres. From 45 we have received the permission to analyse their Guthrie card.
29 children had IRT-values above 60 ng/ml (2009: 4/4, 2008: 5/8, 2007: 10/17,
2006: 10/16). Fifteen children had a value between 30 and 60 ng/ml. All these
values were much higher compared to IRT-measurements from Guthrie cards of
the control group (8−10 healthy children from the same day of each patient: mean
IRT 15.4 ng/ml). There was only one false negative IRT result: This child was
diagnosed with atypical CF in the ﬁrst week of life using molecular diagnostic
(F508 del/R31c) as both parents were known heterozygous CF carriers. The child
is pancreatic sufﬁcient and would have been missed in the proposed algorithm as
the IRT was identical to the control group (9.72 vs. 9.68 ng/ml) and the sweat test
was normal (Cl=15mmol/l).
Conclusions: All children (but one with an atypical CF) would have been detected
with the planned two step protocol.
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Background: From June 1996 until December 2007 a two-step IRT/DNA-screening
was performed in eastern saxony, Germany. 160674 neonates have been screened
and 38 children with cystic ﬁbrosis (CF) have been diagnosed. We wanted to show
that even if the diagnose is conﬁrmed in the ﬁrst month of life, most children with
CF show already clinical symptoms.
Methods: In all patients with CF we reported birth weight and length, weight
and length at date of diagnosis, clinical pulmonary and gastrointestinal symptoms
reported by the parents at the ﬁrst contact, clinical examination and stool elastase.
Results: Birth weight and length was signiﬁcant lower than birth weight and length
of healthy children in Germany (p = 0.015 for birth weight and p = 0.00 for birth
length). In 50 % of the cases weight and length at date of diagnosis was on a lower
percentile than at birth. In 22% of the cases parents already recognized pulmonary
symptoms like cough or bronchitis and gastrointestinal symptoms like diarrhea,
abdominal pain or insufﬁciant weigth gain. In 24% clinical examination showed
pulmonary symptoms as well and in 81% we found already at that time pancreas
insufﬁciency.
Conclusions: Children with cystic ﬁbrosis in most cases already have clinical
symptoms even if they are diagnosed early by newborn screening. Especially
insufﬁciant weight gain and growth and pancreas insufﬁcency are often not noticed
by parents at that stage of illness and should be treated. Therefore newborn
screening is a nessecary tool for a better treatment in early life of children with
cystic ﬁbrosis.
24 Experience with harmonizing the neonatal CF screening (NSCF)
management via model IRT/PAP/DNA in the Czech Republic
M. Balascakova1, V. Skalicka1, P. Hodkova2, T. Piskackova1, L. Smolikova1,
P. Drˇevinek1, K. Austova1, A. Pickova1, F. Votava3, M. Macek Jr.1. 1University
Hospital Motol, Charles University, CF Centre, Prague, Czech Republic; 2Czech
CF Association, Prague, Czech Republic; 3University Hospital K. Vinohrady,
Charles University, Paediatric, Prague, Czech Republic
IRT/DNA/IRT is nationwide NSCF since 10/2009. Although efﬁcacy conﬁrmed
during pilot study (2005−6), high number of healthy carriers discovered (1:15.4
in selected group). CF more speciﬁc IRT/PAP/DNA now runs in parallel. In
comparison with IRT/DNA/IRT is cost effective but requires higher amount of
sweat tests (ST) (~1%).
Detection of PAP or IRT+PAP increase (at ~3 wks of life) is followed by a ST
laboratory referral. As this moment brings psychological burden to the family,
we prefer contact via the family paediatrician (FP) who has got most up-to-date
information about child and family. Parents sign informed consent with blood spot
DNA analysis at the moment of ST. The ST result notiﬁcation is administered on
the same day by phone. The ﬁrst information about diagnosis (DG) is provided by
CF medical specialist together with psychologist who both follow up the family.
To minimize extreme stress a telephone hot line with a CF psychologist and social
worker is available for parents, personal meeting possible to arrange. Four-day stay
in CF centre is ﬁxed up for intensive airway clearance training, pancreatic enzyme
administration and other instructions coming from all CF team members (social
worker, hygiene rules specialist, geneticist, CF nurse).
Although basic information about NSCF is provided at the maternity unit there
is generally low public awareness about CF. Learning about CF is therefore
very stressful. The education should be positively structured with a focus on
importance of early treatment on positive prognosis, improving life quality and
survival expectancy.
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In 2007 CA began CF NBS using an algorithm that includes full CFTR gene analysis
(via scanning-sequencing technology), minimizing the false positive rate. Infants
with 2 mutations detected are referred to CF Centers (CFCs) for evaluation and
conﬁrmatory SC testing. While a positive SC test represents deﬁnitive diagnostic
criteria for CF, individuals with CF could have SC outside of the diagnostic range.
We are currently conducting a prospective study of SC in infants identiﬁed by CA
CF NBS. Here we present the SC results of infants identiﬁed in the ﬁrst 2 years of
CF NBS by CFTR genotype. CFTR mutations were categorized according to their
class into Groups A (classes I, II, III), B (classes IV, V) or C (Unclassiﬁed). Median
SC results were analyzed by genotype groups (mutation1/mutation2: A/A, A/B,
A/C, B/C, C/C). 429 newborns had positive results; 95% (N= 406) had 1 SC test
performed. Among screen positive infants meeting the inclusion criteria (N = 285),
the A/C mutation group was the most prevalent (45%) followed by the A/A group
(33%). Median initial SC (mmol/L) was highest among infants in group A/A (94.5)
and lowest among infants in group C/C (13.5). Despite low SC in all groups but
A/A, the percentage of infants in each group with a ﬁnal diagnosis of CF was
signiﬁcant (A/A 90%, A/B 42%, A/C 20%, B/C 29%, C/C 19%). By initial SC
category, 6% of infants with a diagnosis of CF had values 29, 12% between
30−59 and 71% 60mEql/L. 11% did not have a SC test. Although genotype
and SC are correlated, neither is a perfect predictor of ﬁnal diagnosis. This study
emphasizes the importance of longitudinal follow up at CFCs regardless of initial
SC results.
